CZ20014392A3 - Vakcína AND pro domácí a sportovní zvířata - Google Patents
Vakcína AND pro domácí a sportovní zvířata Download PDFInfo
- Publication number
- CZ20014392A3 CZ20014392A3 CZ20014392A CZ20014392A CZ20014392A3 CZ 20014392 A3 CZ20014392 A3 CZ 20014392A3 CZ 20014392 A CZ20014392 A CZ 20014392A CZ 20014392 A CZ20014392 A CZ 20014392A CZ 20014392 A3 CZ20014392 A3 CZ 20014392A3
- Authority
- CZ
- Czechia
- Prior art keywords
- vaccine
- encoding
- gene
- adn
- plasmid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 159
- 241001465754 Metazoa Species 0.000 title claims abstract description 30
- 239000012634 fragment Substances 0.000 claims abstract description 134
- 239000000427 antigen Substances 0.000 claims abstract description 103
- 108091007433 antigens Proteins 0.000 claims abstract description 103
- 102000036639 antigens Human genes 0.000 claims abstract description 103
- 239000002773 nucleotide Substances 0.000 claims abstract description 57
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 57
- 238000012217 deletion Methods 0.000 claims abstract description 32
- 230000037430 deletion Effects 0.000 claims abstract description 32
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 28
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 claims abstract description 16
- -1 cationic lipid Chemical class 0.000 claims abstract description 10
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract 8
- 239000013612 plasmid Substances 0.000 claims description 186
- 108090000623 proteins and genes Proteins 0.000 claims description 161
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 claims description 40
- 239000013613 expression plasmid Substances 0.000 claims description 38
- 241000282465 Canis Species 0.000 claims description 30
- 241000283073 Equus caballus Species 0.000 claims description 30
- 241000282472 Canis lupus familiaris Species 0.000 claims description 27
- 241000282324 Felis Species 0.000 claims description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 22
- 239000013604 expression vector Substances 0.000 claims description 20
- 238000007918 intramuscular administration Methods 0.000 claims description 19
- 244000052769 pathogen Species 0.000 claims description 19
- 241000282326 Felis catus Species 0.000 claims description 18
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 18
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 17
- 241000283086 Equidae Species 0.000 claims description 16
- 101150029683 gB gene Proteins 0.000 claims description 14
- 101150002378 gC gene Proteins 0.000 claims description 14
- 101150036031 gD gene Proteins 0.000 claims description 14
- 238000007920 subcutaneous administration Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 12
- 101150034814 F gene Proteins 0.000 claims description 11
- 101150039660 HA gene Proteins 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 9
- 101150002418 cpi-2 gene Proteins 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 7
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 claims description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 5
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 5
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 5
- 241000711798 Rabies lyssavirus Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000711475 Feline infectious peritonitis virus Species 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 241000193449 Clostridium tetani Species 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 241000320378 Calhevirus 1 Species 0.000 claims 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 1
- 102100031235 Chromodomain-helicase-DNA-binding protein 1 Human genes 0.000 claims 1
- 101710170296 Chromodomain-helicase-DNA-binding protein 1 Proteins 0.000 claims 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
- 241000230501 Equine herpesvirus sp. Species 0.000 claims 1
- 241000704611 Fig cryptic virus Species 0.000 claims 1
- 241000712469 Fowl plague virus Species 0.000 claims 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 1
- 101150062179 II gene Proteins 0.000 claims 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 1
- 241000710951 Western equine encephalitis virus Species 0.000 claims 1
- QAYICIQNSGETAS-UHFFFAOYSA-N dazomet Chemical compound CN1CSC(=S)N(C)C1 QAYICIQNSGETAS-UHFFFAOYSA-N 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 108010091742 peptide F Proteins 0.000 claims 1
- RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical group C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 35
- 230000004224 protection Effects 0.000 abstract description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 10
- 238000012986 modification Methods 0.000 abstract description 6
- 230000004048 modification Effects 0.000 abstract description 6
- 238000003780 insertion Methods 0.000 abstract description 5
- 230000037431 insertion Effects 0.000 abstract description 5
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract description 5
- 241001529453 unidentified herpesvirus Species 0.000 abstract description 3
- 241000711504 Paramyxoviridae Species 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 238000011238 DNA vaccination Methods 0.000 abstract 2
- 108091092195 Intron Proteins 0.000 abstract 1
- 102100035436 Complement factor D Human genes 0.000 description 148
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 65
- 108091034117 Oligonucleotide Proteins 0.000 description 63
- 239000013598 vector Substances 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 41
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 36
- 241000712083 Canine morbillivirus Species 0.000 description 32
- 108090000288 Glycoproteins Proteins 0.000 description 31
- 102000003886 Glycoproteins Human genes 0.000 description 31
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 30
- 101710154606 Hemagglutinin Proteins 0.000 description 29
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 29
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 29
- 101710176177 Protein A56 Proteins 0.000 description 29
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 28
- 239000000185 hemagglutinin Substances 0.000 description 28
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 description 27
- 239000011159 matrix material Substances 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 230000029087 digestion Effects 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 108050002093 Haemagglutinin-neuraminidases Proteins 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 238000007792 addition Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000028993 immune response Effects 0.000 description 14
- 108010047620 Phytohemagglutinins Proteins 0.000 description 12
- 238000005457 optimization Methods 0.000 description 12
- 230000001885 phytohemagglutinin Effects 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 108010062580 Concanavalin A Proteins 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 125000002091 cationic group Chemical group 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 206010014599 encephalitis Diseases 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 5
- 101150008820 HN gene Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000701931 Canine parvovirus Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000714201 Feline calicivirus Species 0.000 description 4
- 241000714165 Feline leukemia virus Species 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000711506 Canine coronavirus Species 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 241000701925 Feline parvovirus Species 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 3
- 230000000240 adjuvant effect Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000010841 mRNA extraction Methods 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- 241000700587 Alphaherpesvirinae Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010015149 Equid herpesvirus 4 glycoprotein D Proteins 0.000 description 2
- 101150080073 G1 gene Proteins 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- CBOVGCBFBDQJBE-UHFFFAOYSA-N 3-aminopropyl-(2,3-didodecoxypropyl)-dimethylazanium Chemical compound CCCCCCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCCCCCC CBOVGCBFBDQJBE-UHFFFAOYSA-N 0.000 description 1
- BITVSRNAFFZUFW-UHFFFAOYSA-N 5-ethyl-6-phenylphenanthridin-5-ium-3,8-diamine;chloride Chemical compound [Cl-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 BITVSRNAFFZUFW-UHFFFAOYSA-N 0.000 description 1
- 101150102327 68 gene Proteins 0.000 description 1
- 101150032532 69 gene Proteins 0.000 description 1
- 101150092712 72 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100083503 Caenorhabditis elegans acl-1 gene Proteins 0.000 description 1
- 108010066310 Canid herpesvirus 1 glycoprotein B Proteins 0.000 description 1
- 108010073458 Canid herpesvirus 1 glycoprotein C Proteins 0.000 description 1
- 108010037810 Canid herpesvirus 1 glycoprotein D Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000255930 Chironomidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010012716 Felid herpesvirus 1 glycoprotein B Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001135960 Murine rotavirus Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037569 Purulent discharge Diseases 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 108700012261 Rotavirus VP7 Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000009411 base construction Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000008993 bowel inflammation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LYQFWZFBNBDLEO-UHFFFAOYSA-M caesium bromide Chemical compound [Br-].[Cs+] LYQFWZFBNBDLEO-UHFFFAOYSA-M 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000819 phase cycle Methods 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/175—Canine distemper virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9907604A FR2794648B1 (fr) | 1999-06-10 | 1999-06-10 | Vaccins adn pour animaux de compagnie et de sport |
| US14449099P | 1999-07-19 | 1999-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20014392A3 true CZ20014392A3 (cs) | 2002-06-12 |
Family
ID=26234993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20014392A CZ20014392A3 (cs) | 1999-06-10 | 2000-06-08 | Vakcína AND pro domácí a sportovní zvířata |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1185662B1 (https=) |
| JP (1) | JP2003502345A (https=) |
| KR (1) | KR100768114B1 (https=) |
| AR (1) | AR024334A1 (https=) |
| AU (1) | AU782154C (https=) |
| BR (1) | BR0011732B1 (https=) |
| CA (1) | CA2375320C (https=) |
| CZ (1) | CZ20014392A3 (https=) |
| NZ (1) | NZ515993A (https=) |
| PL (1) | PL210451B1 (https=) |
| WO (1) | WO2000077043A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2804028B1 (fr) * | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
| FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
| FR2825280B1 (fr) * | 2001-06-01 | 2005-04-15 | Merial Sas | Vaccination contre le virus de l'immunodeficience feline |
| WO2005049794A2 (en) | 2003-11-13 | 2005-06-02 | University Of Georgia Research Foundation, Inc. | Methods of characterizing infectious bursal disease virus |
| RS51324B (sr) | 2005-04-25 | 2010-12-31 | Merial Ltd. | Vakcine protiv nipah virusa |
| EP1954308B1 (en) * | 2005-09-16 | 2011-09-07 | Merial Ltd. | Stabilizers for freeze-dried vaccines |
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| EP2276495B1 (en) | 2008-04-17 | 2018-11-21 | PDS Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| EP3756684A1 (en) | 2009-05-22 | 2020-12-30 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| US20130197612A1 (en) * | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
| JP6055776B2 (ja) | 2010-11-24 | 2016-12-27 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 |
| AU2012340712B2 (en) | 2011-11-23 | 2017-09-14 | Genocea Biosciences, Inc. | Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| CA2876656C (en) * | 2012-06-15 | 2023-09-26 | Pds Biotechnology Corporation | Cationic lipid vaccine compositions and methods of use |
| CN113144188A (zh) | 2012-09-21 | 2021-07-23 | Pds生物科技公司 | 改进的疫苗组合物和使用方法 |
| CN104164409A (zh) * | 2014-07-18 | 2014-11-26 | 中国人民解放军军事医学科学院军事兽医研究所 | 含有犬gmcsf基因的重组犬瘟热病毒及其制备方法 |
| CN104958283A (zh) * | 2015-06-02 | 2015-10-07 | 北京盛大康成医疗技术有限公司 | 弱碱性皮肤粘膜清洗消毒组合物及其制造方法和用途 |
| CA3005251A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| KR101694676B1 (ko) | 2015-12-10 | 2017-01-10 | 우진 비앤지 주식회사 | 말 선역 질병원인 국내 분리 스트렙토코커스 이콰이 균주 및 이를 포함하는 백신 |
| US10350288B2 (en) | 2016-09-28 | 2019-07-16 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
| WO2019113200A1 (en) | 2017-12-05 | 2019-06-13 | Pds Biotechnology Corporation | Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes |
| US20220054616A1 (en) | 2019-01-04 | 2022-02-24 | Boehringer Ingelheim Animal Health USA Inc. | Attenuated Bordetella Bronchiseptica Strains, Oral Vaccines Containing the Attenuated Strains, and Methods of Making & Use Thereof |
| IL291968A (en) * | 2019-10-09 | 2022-06-01 | Mayo Found Medical Education & Res | Rabies megaloglutin virus and fusion polypeptides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| EP1624068A1 (en) * | 1993-06-01 | 2006-02-08 | Life Technologies Inc. | Genetic immunization with cationic lipids |
| WO1995026751A1 (en) * | 1994-03-30 | 1995-10-12 | Virogenetics Corporation | NUCLEOTIDE AND AMINO ACID SEQUENCES OF CANINE HERPESVIRUS gB, gC and gD AND USES THEREFOR |
| JPH11504631A (ja) * | 1995-04-25 | 1999-04-27 | バイカル インコーポレイテッド | Ｄｎａ／脂質複合体の単一バイアル製剤 |
| ES2109189B1 (es) * | 1996-03-14 | 1998-05-16 | Iberica Cyanamid | Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas. |
| EP0954582A1 (en) * | 1996-04-29 | 1999-11-10 | Andreas Prof. Zurbriggen | Polynucleotide vaccine against canine distemper |
| FR2751226B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
| FR2751223B1 (fr) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
| FR2751227B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
| WO1998040499A1 (en) * | 1997-03-10 | 1998-09-17 | Heather Lynn Davis | Gene delivery to mucosal epithelium for immunization or therapeutic purposes |
| AU1131200A (en) * | 1998-10-23 | 2000-05-15 | Heska Corporation | Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
-
2000
- 2000-06-08 CA CA2375320A patent/CA2375320C/en not_active Expired - Lifetime
- 2000-06-08 BR BRPI0011732-3A patent/BR0011732B1/pt not_active IP Right Cessation
- 2000-06-08 PL PL352212A patent/PL210451B1/pl unknown
- 2000-06-08 NZ NZ515993A patent/NZ515993A/en not_active IP Right Cessation
- 2000-06-08 KR KR1020017015911A patent/KR100768114B1/ko not_active Expired - Lifetime
- 2000-06-08 CZ CZ20014392A patent/CZ20014392A3/cs unknown
- 2000-06-08 JP JP2001503899A patent/JP2003502345A/ja active Pending
- 2000-06-08 EP EP00940474A patent/EP1185662B1/fr not_active Expired - Lifetime
- 2000-06-08 AU AU55405/00A patent/AU782154C/en not_active Expired
- 2000-06-08 WO PCT/FR2000/001592 patent/WO2000077043A2/fr not_active Ceased
- 2000-06-12 AR ARP000102879A patent/AR024334A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003502345A (ja) | 2003-01-21 |
| CA2375320A1 (en) | 2000-12-21 |
| BR0011732B1 (pt) | 2014-02-04 |
| WO2000077043A3 (fr) | 2001-07-19 |
| PL210451B1 (pl) | 2012-01-31 |
| PL352212A1 (en) | 2003-08-11 |
| AU782154B2 (en) | 2005-07-07 |
| AU5540500A (en) | 2001-01-02 |
| KR100768114B1 (ko) | 2007-10-17 |
| AU782154C (en) | 2006-02-09 |
| EP1185662A2 (fr) | 2002-03-13 |
| WO2000077043A2 (fr) | 2000-12-21 |
| CA2375320C (en) | 2013-02-19 |
| BR0011732A (pt) | 2002-03-05 |
| KR20020012271A (ko) | 2002-02-15 |
| NZ515993A (en) | 2004-04-30 |
| EP1185662B1 (fr) | 2011-03-02 |
| AR024334A1 (es) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ20014392A3 (cs) | Vakcína AND pro domácí a sportovní zvířata | |
| JP7548902B2 (ja) | アフリカ豚熱ウイルスワクチン | |
| US20230310571A1 (en) | Human metapneumovirus vaccines | |
| JP2003502345A5 (https=) | ||
| JP2023526422A (ja) | コロナウイルス抗原組成物及びそれらの使用 | |
| CZ300593B6 (cs) | Vakcína proti viru chripky savcu celedi konovitých EIV, použití této vakcíny a souprava tuto vakcínu obsahující | |
| US20230174588A1 (en) | A vaccine against sars-cov-2 and preparation thereof | |
| KR20150058139A (ko) | 양이온성 지질 백신 조성물 및 이용 방법 | |
| WO2024055273A1 (zh) | 一种狂犬病mRNA疫苗、其制备及应用 | |
| US7078388B2 (en) | DNA vaccines for farm animals, in particular bovines and porcines | |
| CA2398229C (en) | Improved dna vaccines for production-type animals | |
| AU2005202233B2 (en) | DNA vaccines for pets and sport animals | |
| CN117721150A (zh) | 一种狂犬病mRNA疫苗、其制备及应用 | |
| RU2283867C2 (ru) | Днк-вакцина (варианты) и иммуногенная композиция против чумки собак | |
| EP1721982B1 (en) | Chimeric lyssavirus nucleic acids and polypeptides |